Berkeley Review Dismisses Critics' Fears

See allHide authors and affiliations

Science  17 Jan 2003:
Vol. 299, Issue 5605, pp. 332
DOI: 10.1126/science.299.5605.332

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


A recently completed internal review of the University of California, Berkeley's 5-year, $25 million agreement with Novartis concludes that the only real drawback was the negative publicity generated by critics of the high-profile collaboration. But others say the study's focus is too narrow, and that negotiating the pact in secret was a big mistake that should never be repeated.